Brind.

TD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.

1 report, 1 independent Updated 00:00

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

MarketBeat TD Cowen

Keep exploring

The entities involved

MarketBeat
American personal finance blog
- Brookfield Wealth Solutions and Paysign are competing for investment capital, while MarketBeat provides analyst recommendations for Paysign.14:35
- MarketBeat is providing average rating data as Royal Bank of Canada issues a price target report regarding ConocoPhillips.14:20
TD Cowen
American investment bank
- Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.10:23
- Cantor Fitzgerald raised price targets and reaffirmed ratings, while TD Cowen adjusted its ratings for Paylocity on August 7, 2026.Mon 23:14

Related events

MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.Sun 10:06
MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.Thu 13:53
Leerink Partners assumed coverage on Equillium shares, with data reported by MarketBeat from Nasdaq listed stocks.Wed 07:43
Bank of America raised its target price on Morgan Stanley shares, while TD Cowen assumed coverage and MarketBeat reported analyst ratings.Oct 8
MarketBeat is comparing Lisata Therapeutics and Praxis Precision Medicines for investment and providing analyst ratings for Praxis.Oct 11

Coverage

Newest first; wire copies grouped

00:00themarketsdaily.com